Do I automatically become part of the Dupixent MDL if I was diagnosed with CTCL?

No. Patients do not automatically become part of the Dupixent multidistrict litigation simply because they were diagnosed with cutaneous T-cell lymphoma (CTCL), mycosis fungoides, Sézary syndrome, or another related lymphoma. To participate in the litigation, an individual must generally file a lawsuit and provide evidence supporting their claim, including medical records, pathology reports, and documentation showing Dupixent use. Eligibility depends on the specific facts of each case, including the timing of treatment, diagnosis, and other medical factors. An attorney can review your records and determine whether your claim may qualify for inclusion in the ongoing Dupixent MDL.

What documents may help support a Dupixent lawsuit?

Medical documentation is often one of the most important parts of evaluating a Dupixent claim. Attorneys use these records to establish when Dupixent was prescribed, when symptoms began, when a lymphoma diagnosis was made, and how the condition affected the patient’s life. The specific documents available can vary from case to case, but several types of records are commonly reviewed during the investigation process. Documents that may help support a Dupixent lawsuit include: <ul> <li>Dupixent prescription records</li> <li>Pharmacy dispensing records</li> <li>Dermatology treatment records</li> <li>Oncology records</li> <li>Skin biopsy results</li> <li>Pathology reports confirming CTCL, mycosis fungoides, or Sézary syndrome</li> <li>Bloodwork and imaging studies</li> <li>Hospital and specialist records</li> <li>Medical bills and treatment expenses</li> <li>Employment records showing lost wages or missed work</li> <li>Death certificates and estate documents in wrongful death claims</li> </ul> Even if some records are unavailable, an attorney may be able to help obtain the documentation needed to evaluate a potential claim.

What studies are being cited in the Dupixent litigation?

Several published studies have become important to the ongoing Dupixent litigation because they examine whether certain patients may face a higher risk of cutaneous T-cell lymphoma (CTCL) after using the drug. One frequently cited retrospective matched cohort study published in Dermatologic Therapy reported that Dupixent users had a significantly higher rate of CTCL diagnoses compared to non-users. Researchers have also analyzed patients with severe atopic dermatitis to better understand whether lymphoma cases represent previously undiagnosed disease, disease progression, or another mechanism. More recently, a population based cohort study involving asthma patients reported elevated lymphoma rates among certain dupilumab users, expanding the scientific debate beyond individuals receiving treatment for skin conditions. Although these studies do not establish causation, they are expected to play an important role as experts evaluate the evidence in the Dupixent MDL.

Is the FDA investigating Dupixent's potential lymphoma risks?

Yes. In March 2025, the FDA added Dupixent to its list of Potential Signals of Serious Risks and began evaluating reports involving cutaneous T-cell lymphoma (CTCL) and related lymphomas. Dupixent works by targeting the IL-4 and IL-13 pathways, two components of the immune system involved in inflammatory diseases such as eczema and asthma. Recent research has also reported a 79% higher risk of lymphoma among certain asthma patients treated with Dupixent compared to patients receiving other asthma therapies. As part of the ongoing litigation, many law firms require evidence that a patient used Dupixent for at least three months before receiving a T-cell lymphoma diagnosis, although eligibility can vary depending on the facts of each case. The FDA continues to review available evidence and is evaluating whether additional regulatory action or changes to Dupixent’s safety labeling may be warranted.

Why does it matter whether the Dupixent litigation is an MDL or a class action?

The distinction matters because it affects how your claim is handled and how any potential compensation is determined. In a class action, one or several representative plaintiffs pursue claims on behalf of a larger group, and any settlement or judgment is generally shared among eligible class members. In the Dupixent multidistrict litigation (MDL), each plaintiff maintains an individual lawsuit, meaning their medical history, diagnosis, damages, and circumstances are evaluated separately. This is particularly important in pharmaceutical cases because patients often experience different injuries, treatment outcomes, medical expenses, and long-term effects. For individuals diagnosed with CTCL, mycosis fungoides, Sézary syndrome, or another lymphoma after Dupixent use, an MDL provides the efficiency of coordinated litigation while preserving the opportunity to pursue compensation based on their own unique losses.

Chicago

Case Types We Handle

Edwardsville

Case Types We Handle

St. Louis

Case Types We Handle

Illinois

Missouri

Other Dangerous Drugs

Dangerous Drugs

Other Defective Products

Defective Products

Other Exposure Cases

Chemical Exposure

About

TorHoerman Law

Our firm is about people. That is our motto and that will always be our reality.

We do our best to get to know our clients, understand their situations, and get them the compensation they deserve.

At TorHoerman Law, we believe that if we continue to focus on the people that we represent, and continue to be true to the people that we are – justice will always be served.

Chicago Office

Edwardsville Office

St. Louis Office

About

Our Team

Without our team, we would’nt be able to provide our clients with anything close to the level of service they receive when they work with us.

The TorHoerman Law Team commits to the sincere belief that those injured by the misconduct of others, especially large corporate profit mongers, deserve justice for their injuries.

Our team is what has made TorHoerman Law a very special place since 2009.

Chicago Office

Edwardsville Office

St. Louis Office

About

Resources

Other Resources

Dangerous Drugs

Dangerous Drugs

Dangerous Drugs

The team at TorHoerman Law has dedicated their lives to representing individuals injured at no fault of their own do to the negligent & greed-driven actions of pharmaceutical companies. Our experienced attorneys handle an array of bad drug lawsuits ranging from over-the-counter medications, prescribed medications, supplements, medical devices and more.
Contact TorHoerman Law today to get a free, no-obligation case consultation from an experienced bad drug lawyer or use our chatbot below to get an instant online evaluation.